Secondary Logo

Institutional members access full text with Ovid®

Share this article on:

Dupilumab as a Treatment for Allergic Contact Dermatitis

Chipalkatti, Naina, BS; Lee, Nicole, BA; Zancanaro, Pedro, MD; Dumont, Nicole; Donovan, Courtney, RN; Rosmarin, David, MD

doi: 10.1097/DER.0000000000000414
LETTERS

Tufts University School of Medicine Boston, MA

Tufts Medical Center, Boston, MA

Tufts Medical Center, Boston, MA DRosmarin@tuftsmedicalcenter.org

D.R. serves as a consultant to Regeneron, Pfizer, Abbvie, Janssen, Celgene, Dermavant, and Novartis and is on the speaker’s bureau for Regeneron, Sanofi, Pfizer, Abbvie, Janssen, Celgene, Novartis, and Eli Lilly.

This study was reviewed and approved by Tufts Health Sciences IRB #12791.

© 2018 American Contact Dermatitis Society
You currently do not have access to this article

To access this article:

Note: If your society membership provides full-access, you may need to login on your society website